Although activating mutations in EGFR are prevalent in NSCLC patients, inhibition of wild-type EGFR has shown success in pancreatic cancer,10 head and neck cancer11 and colorectal cancer.12 Ultimately, these studies have led to the FDA approval of EGFR ligand blocking antibodies (cetuximab and panitumumab) for the treatment of colorectal and head and neck cancers. Here, EGFR is linked to colorectal cancer.